BIO
Bio-Rad Laboratories Inc
NYSE: BIO · HEALTHCARE · MEDICAL DEVICES
$275.15
-1.50% today
Updated 2026-04-29
Market cap
$7.43B
P/E ratio
9.88
P/S ratio
2.88x
EPS (TTM)
$27.85
Dividend yield
—
52W range
$211 – $343
Volume
0.3M
WallStSmart proprietary scores
57
out of 100
Grade: C+
Hold
Investment rating
2.7
Growth
F8.5
Quality
A6.5
Profitability
B6.7
Valuation
B3/9
Piotroski F-Score
Weak
3.1
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$302.50
+9.94%
12-Month target
$271.22
-1.43%
Intrinsic (DCF)
$266.96
Margin of safety
-10.01%
0 Strong Buy1 Buy3 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Altman Z 3.11 — safe zone
+ Profit margin 29.40% — above average
+ Free cash flow $119.10M — positive
+ Debt/equity 0.21x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- 10.01% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $2.80B | $2.67B | $2.57B | $2.58B | $2.58B |
| Net income | $-3.63B | $-637.32M | $-1.84B | $759.90M | $720.00M |
| EPS | — | — | — | — | $27.85 |
| Free cash flow | $80.29M | $218.26M | $266.20M | $374.60M | $119.10M |
| Profit margin | -129.45% | -23.86% | -71.86% | 29.42% | 29.40% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2025-11-06 | BARRY, JAMES | Sale | 700 | $306.18 |
| 2025-10-24 | DIVINCENZO, JONATHAN P. | Sale | 1,869 | — |
| 2025-10-24 | DIVINCENZO, JONATHAN P. | Buy | 1,869 | — |
Peer comparison
Smart narrative
Bio-Rad Laboratories Inc trades at $275.15. representing a P/E of 9.88x trailing earnings. Our Smart Value Score of 57/100 indicates the stock is fair. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 3.11, it sits in the safe zone. TTM revenue stands at $2.58B. with profit margins at 29.40%. Our DCF model estimates intrinsic value at $266.96.
Frequently asked questions
What is Bio-Rad Laboratories Inc's stock price?
Bio-Rad Laboratories Inc (BIO) trades at $275.15.
Is Bio-Rad Laboratories Inc overvalued?
Smart Value Score 57/100 (Grade C+, Hold). DCF value $266.96.
What is the price target of Bio-Rad Laboratories Inc (BIO)?
The analyst target price is $302.50, representing +9.9% upside from the current price of $275.15.
What is the intrinsic value of Bio-Rad Laboratories Inc (BIO)?
Based on our DCF model, intrinsic value is $266.96, a -10.0% margin of safety versus $275.15.
What is Bio-Rad Laboratories Inc's revenue?
TTM revenue is $2.58B.
Piotroski F-Score?
3/9 — weak financial health.
Altman Z-Score?
3.11 — safe zone.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio2.88x
ROE10.80%
Beta1.16
50D MA$277.23
200D MA$292.01
Shares out0.02B
Float0.02B
Short ratio—
Avg volume0.3M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—